Chaperonin containing TCP1 subunit 5 is a tumor associated antigen of non-small cell lung cancer
Metrics: PDF 1551 views | HTML 2707 views | ?
Hongjun Gao1,*, Min Zheng2,*, Sijin Sun5,*, Hongwu Wang3, Zhigang Yue1, Yun Zhu1, Xiaochen Han2, Junquan Yang2, Yanqiu Zhou1,3, Yiran Cai4 and Wanning Hu2
1Department of Clinical Laboratory, China Meitan General Hospital, Beijing, PR China
2Department of Oncology, Tangshan People’s Hospital & Tangshan Cancer Hospital, North China University of Science and Technology, Tangshan, PR China
3Department of Oncology, China Meitan General Hospital, Beijing, PR China
4Department of Pathology, Beijing Chest Hospital, Capital Medical University & Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, PR China
5Department of Clinical Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, PR China
*These authors have contributed equally to this work
Hongjun Gao, email: [email protected]
Yanqiu Zhou, email: [email protected]
Wanning Hu, email: [email protected]
Yiran Cai, email: [email protected]
Keywords: CCT5, non-small cell lung cancer, CEA, CYFRA 21-1
Received: February 24, 2017 Accepted: June 18, 2017 Published: July 18, 2017
Novel tumor antigens and their related autoantibodies have tremendous potential for early diagnosis of non-small cell lung cancer (NSCLC). In this study, we identify antigens from NSCLC tissue and autoantibodies in sera of patients with NSCLC using a modified proteomics-based approach. We seperated and identified four NSCLC-associated proteins extracted from the cytosol in tumor tissues by mini-two-dimensional gel electrophoresis, followed by Western blot and hybridization with individual sera for confirmation of antibody binding. Of the proteins we identified, we selected 58 kDa chaperonin containing TCP1(T-Complex Protein 1) subunit 5 (CCT5) for validation. Serum levels of carcinoembryonic antigen (CEA) and cytokeratin 19 fragments (CYFRA 21-1) were measured in all serum samples with an immunoluminometric assay and a receiver operating characteristic (ROC) curve was analyzed for autoantibodies against CCT5, CEA and CYFRA 21-1. The results show that CCT5 can induce an autoantibody response in NSCLC sera and show higher expression in NSCLC tissues by immunohistochemistry and Western blot. Anti-CCT5 autoantibody was found in 51% (23/45) of patients with NSCLC, but only 2.5% (1/40) in non-tumor individual controls. A receiver operating characteristic curve constructed with a panel of autoantibodies against CCT5 (AUC=0.749), CEA (AUC=0.6758), and CYFRA 21-1(AUC=0.760) show a sensitivity of 51.1% and 97.5% specificity in discriminating NSCLC from matched controls. These results indicate the potential utility of screening autoantibodies in sera, show that CCT5 could be used as a biomarker in cancer diagnosis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.